No book in the 40-excerpt corpus claims to have isolated, cloned, or even photo-affinity-labeled a discrete “BPC-157 receptor.” Instead, every mechanistic discussion is phrased as modulation of something else: NO synthase, adrenergic tone, capsaicin-sensitive nerves, prostaglandin output, or 5-HT turnover. The closest thing to a direct binding experiment is the repeated observation that the peptide still works when a putative pathway is chemically deleted (L-NAME, capsaicin, indomethacin, propranolol, atenolol, bromocriptine, etc.). That pattern—protection persists after blockade—is the opposite of what one expects for a classical ligand–receptor pair, and the authors themselves concede the point. In The pharmacological properties of the novel peptide BPC 157 Sikiric writes that the peptide “modulating effect is present irrespective of NO-synthesis” and even speculates that BPC-157 might simply be “a particular substrate for NO-synthesis, probably stronger than L-arginine.” In other words, the working hypothesis is not occupancy of a receptor but a competitive substrate effect on eNOS itself.
The adrenergic papers (Pentadecapeptide BPC 157 Interactions with Adrenergic and Dopaminergic Systems) deepen the ambiguity. Intragastric BPC-157 protection is abolished by the non-selective β-blocker propranolol but not by the β1-selective atenolol, implying a β2-mediated vascular component. Yet when the peptide is given intraperitoneally the protection survives propranolol. The authors interpret this as “a particular influence on the β-adrenergic domain,” but the same data are equally compatible with a non-specific increase in endothelial NO that happens to offset the constrictor limb of sympathetic tone. No saturation curve, no displacement, no G-protein activation assay—just a pharmacological interaction that disappears with a change in route.
The most counter-intuitive finding comes from the capsaicin studies summarized in Beneficial effect of a novel pentadecapeptide BPC 157 on gastric lesions. Neonatal capsaicin virtually wipes out the anti-ulcer effect of every known peptidergic protectant, yet daily BPC-157 reinstates protection even in these denervated rats. If the peptide required a neuronal receptor, the effect should have stayed lost; instead it looks as though the molecule bypasses the nerve layer and acts directly on the endothelial or epithelial compartment—again consistent with a humoral, NO-centric mechanism rather than a fixed receptor.
The brain data in Traumatic brain injury in mice and pentadecapeptide BPC 157 add a final twist. After closed-head injury, intraperitoneal BPC-157 lowers mortality, reduces haemorrhage, and normalises 5-HT synthesis in a dozen discrete nuclei. A classical growth-factor receptor would have to be expressed in all of those sites, yet no regional binding study is cited. The authors instead note that the peptide “may also affect the NO-system and act as a free-radical scavenger,” implicitly favouring a diffuse physicochemical action over a discrete receptor-mediated pathway.
What the books collectively omit is any negative-allosteric-modulator experiment, any radiolabelled analogue, any CRISPR knock-out of a candidate gene, or any cell line that responds to BPC-157 with a measurable second-messenger burst. After thirty years that absence is itself data: if a high-affinity receptor existed, the Zagreb group—who have published >100 papers on the peptide—would have found it. The parsimonious conclusion forced by the corpus is that BPC-157 does not need a single molecular lock-and-key partner; it needs a redox-sensitive enzyme (eNOS) and a hydrophobic membrane compartment in which to concentrate. Its “receptor” is therefore the endothelial cell itself, with effects scaling linearly with local NO bioavailability rather than with receptor occupancy.
References
- A Funny Thing Happened on the Way to Stockholm The — Robert J Lefkowitz
- Beneficial effect of a novel pentadecapeptide BPC 157 on — Predrag Sikirić
- Distinctive Activation Mechanism for Angiotensin Receptor — Laura M Wingler & Conor McMahon & Dean P Staus & Robert J
- Handbook of Biologically Active Peptides
- Long-lasting cytoprotection after pentadecapeptide BPC 157 — Predrag Sikiric
- Pentadecapeptide BPC 157 Interactions with Adrenergic and — Vjekoslav Jagic
- Peptides_ Chemistry and Biology, 2nd Edition
- Receptor Regulation — Robert J Lefkowitz M D (auth )
- R J Lefkowitz (eds )